Recent Updates
Recently added Catalysts
BOLT Negative Sentiment Score: 25/100

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Monday, June 24, 2024 2 min read
Key Takeaway: The Portnoy Law Firm has initiated an investigation into Bolt Biotherapeutics, Inc. regarding possible securities fraud, potentially leading to a class action on behalf of investors. This follows a significant announcement on May 14, 2024, where Bolt stated it would halt development of its lead asset and reduce its workforce by 50%. Consequently, Bolt's stock experienced a dramatic fall of over 37%, prompting analysts to downgrade the company's stock. Investors who have suffered losses are encouraged to contact the law firm for legal support.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company is under investigation for possible securities fraud.
  • Bolt announced it would cease development of its lead asset, BDC-1001.
  • The workforce will be reduced by approximately 50%.
  • After the announcement, the stock price fell over 37%.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Bolt investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On May 14, 2024, Bolt announced in a press release that the Company would “cease further development of trastuzumab imbotolimod (BDC-1001)”, Bolt’s lead asset, “and reduce workforce by approximately 50%”. Following Bolt’s announcement, multiple analysts downgraded the Company’s stock.
On this news, Bolt’s stock price fell $00.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
Attorney Advertising

Tags

Bolt Biotherapeutics
Bolt Biotherapeutics Inc

Frequently Asked Questions

What is the purpose of the Portnoy Law Firm's investigation?

The Portnoy Law Firm is investigating potential securities fraud related to Bolt Biotherapeutics.

How can Bolt investors recover their losses?

Investors can contact attorney Lesley Portnoy for a complimentary case evaluation.

What happened to Bolt's stock price on May 15, 2024?

On May 15, 2024, Bolt's stock fell by over 37% to close at $00.83 per share.

What led to the stock price drop for Bolt Biotherapeutics?

The stock drop followed Bolt's announcement to stop developing its lead asset and reduce workforce.

How can I contact Lesley Portnoy for legal rights discussion?

You can contact Lesley Portnoy by phone at 310-692-8883 or via email.

Tags: BOLT Viatris Investor Conferences Healthcare Bolt Biotherapeutics securities fraud class action investors BDC-1001
Last updated: Jun 24, 2024